Mivebresib

N/A

Report date: 2024/07/05 20:00:49
NME

Base Information

Drug NameMivebresib
Drug Alias NameABBV-075
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBromodomain and extra terminal domain protein inhibitors
TargetsBromodomain and extra terminal domain protein
Therapy Area/IndicationsPrimary MyelofibrosisProstatic NeoplasmsSmall Cell Lung Carcinoma +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth AfricaSouth Korea
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbvie Inc
Active IndicationsN/A
Inactive IndicationsPrimary MyelofibrosisProstatic NeoplasmsSmall Cell Lung Carcinoma +[9] 

Other Information

ATC CodeN/A
Related LinksN/A